

# Michael M Gottesman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1872623/publications.pdf>

Version: 2024-02-01

214  
papers

41,003  
citations

8755

75  
h-index

2509

196  
g-index

229  
all docs

229  
docs citations

229  
times ranked

35032  
citing authors

#	ARTICLE	IF	CITATIONS
1	Host gene expression modulated by Zika virus infection of human-293 cells. <i>Virology</i> , 2021, 552, 32-42.	2.4	5
2	Cross-resistance of cisplatin selected cells to anti-microtubule agents: Role of general survival mechanisms. <i>Translational Oncology</i> , 2021, 14, 100917.	3.7	8
3	ATP-binding cassette transporters at the zebrafish blood-brain barrier and the potential utility of the zebrafish as an in vivo model. , 2021, 4, 620-633.		3
4	Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma. , 2021, 62, 16.		4
5	Characterization and tissue localization of zebrafish homologs of the human ABCB1 multidrug transporter. <i>Scientific Reports</i> , 2021, 11, 24150.	3.3	15
6	Mycoplasma Infection Mediates Sensitivity of Multidrug-Resistant Cell Lines to Tiopronin: A Cautionary Tale. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 1434-1439.	6.4	4
7	Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 29609-29617.	7.1	28
8	Understanding the impact of controlled oxygen delivery to 3D cancer cell culture. , 2020, , 661-696.		0
9	Leptin Signaling Affects Survival and Chemoresistance of Estrogen Receptor Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3794.	4.1	14
10	A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer. <i>Experimental Cell Research</i> , 2020, 388, 111860.	2.6	26
11	Multidrug transporters: recent insights from cryo-electron microscopy-derived atomic structures and animal models. <i>F1000Research</i> , 2020, 9, 17.	1.6	25
12	The Evolving AML Genomic Landscape: Therapeutic Implications. <i>Current Cancer Drug Targets</i> , 2020, 20, 532-544.	1.6	8
13	Exome Sequencing of ABCB5 Identifies Recurrent Melanoma Mutations that Result in Increased Proliferative and Invasive Capacities. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1985-1992.e10.	0.7	6
14	Model systems for studying the blood-brain barrier: Applications and challenges. <i>Biomaterials</i> , 2019, 214, 119217.	11.4	50
15	Heterogeneity in refractory acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10494-10503.	7.1	40
16	Spatial control of oxygen delivery to three-dimensional cultures alters cancer cell growth and gene expression. <i>Journal of Cellular Physiology</i> , 2019, 234, 20608-20622.	4.1	17
17	Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells. <i>Cancer Letters</i> , 2019, 457, 110-118.	7.2	39
18	Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function. <i>Drug Metabolism and Disposition</i> , 2019, 47, 715-723.	3.3	17

#	ARTICLE	IF	CITATIONS
19	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. <i>Molecular Pharmacology</i> , 2019, 96, 629-640.	2.3	22
20	Inside Cover Image, Volume 234, Number 11, November 2019. <i>Journal of Cellular Physiology</i> , 2019, 234, ii.	4.1	0
21	Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models. <i>Experimental Cell Research</i> , 2019, 375, 106-112.	2.6	15
22	Revisiting the role of ABC transporters in multidrug-resistant cancer. <i>Nature Reviews Cancer</i> , 2018, 18, 452-464.	28.4	1,181
23	Pluripotent Stem Cell Platforms for Drug Discovery. <i>Trends in Molecular Medicine</i> , 2018, 24, 805-820.	6.7	33
24	Mapping discontinuous epitopes for MRK-16, UIC2 and 4E3 antibodies to extracellular loops 1 and 4 of human P-glycoprotein. <i>Scientific Reports</i> , 2018, 8, 12716.	3.3	21
25	The tuberous sclerosis complex subunit TBC1D7 is stabilized by Akt phosphorylation-mediated 14-3-3 binding. <i>Journal of Biological Chemistry</i> , 2018, 293, 16142-16159.	3.4	11
26	Structures of the Multidrug Transporter P-glycoprotein Reveal Asymmetric ATP Binding and the Mechanism of Polyspecificity. <i>Journal of Biological Chemistry</i> , 2017, 292, 446-461.	3.4	152
27	An automated method measures variability in P-glycoprotein and ABCG2 densities across brain regions and brain matter. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 2062-2075.	4.3	20
28	The Drug Excipient Cyclodextrin Interacts With<scp>d</scp>-Luciferin and Interferes With Bioluminescence Imaging. <i>Molecular Imaging</i> , 2016, 15, 153601211562522.	1.4	4
29	Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier. <i>Scientific Reports</i> , 2016, 6, 20418.	3.3	8
30	Cryo-EM Analysis of the Conformational Landscape of Human P-glycoprotein (ABCB1) During its Catalytic Cycle. <i>Molecular Pharmacology</i> , 2016, 90, 35-41.	2.3	75
31	In Vivo Bioluminescent Imaging of ATP-Binding Cassette Transporter-Mediated Efflux at the Bloodâ€‘Brain Barrier. <i>Methods in Molecular Biology</i> , 2016, 1461, 227-239.	0.9	7
32	The ABCG2 Multidrug Transporter. , 2016, , 195-226.		12
33	Genetic Polymorphisms of P-glycoprotein: Echoes of Silence. , 2016, , 105-134.		3
34	Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein. <i>Drug Metabolism and Disposition</i> , 2016, 44, 275-282.	3.3	54
35	Using the BacMam Baculovirus System to Study Expression and Function of Recombinant Efflux Drug Transporters in Polarized Epithelial Cell Monolayers. <i>Drug Metabolism and Disposition</i> , 2016, 44, 180-188.	3.3	5
36	A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. <i>Molecular Pharmacology</i> , 2016, 89, 263-272.	2.3	21

#	ARTICLE	IF	CITATIONS
37	Humanâ€“Mouse Chimeras with Normal Expression and Function Reveal That Major Domain Swapping Is Tolerated by P-Glycoprotein (ABCB1). <i>Biochemistry</i> , 2016, 55, 1010-1023.	2.5	14
38	Mathematical Modeling Reveals That Changes to Local Cell Density Dynamically Modulate Baseline Variations in Cell Growth and Drug Response. <i>Cancer Research</i> , 2016, 76, 2882-2890.	0.9	28
39	Toward a Better Understanding of the Complexity of Cancer Drug Resistance. <i>Annual Review of Pharmacology and Toxicology</i> , 2016, 56, 85-102.	9.4	261
40	Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. <i>Oncotarget</i> , 2016, 7, 69804-69815.	1.8	14
41	Selectable Markers for Gene Therapy. , 2015, , 701-740.		0
42	Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs. <i>Journal of Biological Inorganic Chemistry</i> , 2015, 20, 1081-1095.	2.6	14
43	The Protein Phosphatase 2A Inhibitor LB100 Sensitizes Ovarian Carcinoma Cells to Cisplatin-Mediated Cytotoxicity. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 90-100.	4.1	36
44	Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients. <i>Journal of Inorganic Biochemistry</i> , 2015, 149, 45-48.	3.5	10
45	Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL. <i>Experimental Cell Research</i> , 2015, 336, 318-328.	2.6	22
46	The Role of Abcb5 Alleles in Susceptibility to Haloperidol-Induced Toxicity in Mice and Humans. <i>PLoS Medicine</i> , 2015, 12, e1001782.	8.4	23
47	Beyond 3D culture models of cancer. <i>Science Translational Medicine</i> , 2015, 7, 283ps9.	12.4	80
48	The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv222.	6.3	110
49	The Inhibitor Ko143 Is Not Specific for ABCG2. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 354, 384-393.	2.5	113
50	Modeling intrinsic heterogeneity and growth of cancer cells. <i>Journal of Theoretical Biology</i> , 2015, 367, 262-277.	1.7	29
51	Identification of a Cryptic Bacterial Promoter in Mouse (mdr1a) P-Glycoprotein cDNA. <i>PLoS ONE</i> , 2015, 10, e0136396.	2.5	5
52	Lost in Translation: Regulation of ABCG2 Expression in Human Embryonic Stem Cells. <i>Journal of Stem Cell Research &amp; Therapy</i> , 2014, 04, .	0.3	3
53	Gil Ashwell, 1916â€“2014. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16232-16233.	7.1	0
54	Inhibition of Glutathione Peroxidase Mediates the Collateral Sensitivity of Multidrug-resistant Cells to Tiopronin. <i>Journal of Biological Chemistry</i> , 2014, 289, 21473-21489.	3.4	37

#	ARTICLE	IF	CITATIONS
55	The Impact of Cell Density and Mutations in a Model of Multidrug Resistance in Solid Tumors. Bulletin of Mathematical Biology, 2014, 76, 627-653.	1.9	40
56	Simplifying the complexity of resistance heterogeneity in metastasis. Trends in Molecular Medicine, 2014, 20, 129-136.	6.7	14
57	Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum Complexes. Cancer Research, 2014, 74, 3913-3922.	0.9	277
58	Targeting the Achilles Heel of Multidrug-Resistant Cancer by Exploiting the Fitness Cost of Resistance. Chemical Reviews, 2014, 114, 5753-5774.	47.7	172
59	Drug Resistance Is Conferred on the Model Yeast <i>Saccharomyces cerevisiae</i> by Expression of Full-Length Melanoma-Associated Human ATP-Binding Cassette Transporter ABCB5. Molecular Pharmaceutics, 2014, 11, 3452-3462.	4.6	14
60	<i>MDR1</i> Synonymous Polymorphisms Alter Transporter Specificity and Protein Stability in a Stable Epithelial Monolayer. Cancer Research, 2014, 74, 598-608.	0.9	103
61	Exploring the complexity of multidrug resistance in cancer (91.1). FASEB Journal, 2014, 28, 91.1.	0.5	0
62	P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway. Biochemical Pharmacology, 2013, 86, 584-596.	4.4	18
63	The Clinical Relevance of Cancer Cell Lines. Journal of the National Cancer Institute, 2013, 105, 452-458.	6.3	479
64	The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance. Cancer Research, 2013, 73, 7168-7175.	0.9	59
65	Nanoscale Drug Delivery Platforms Overcome Platinum-Based Resistance in Cancer Cells Due to Abnormal Membrane Protein Trafficking. ACS Nano, 2013, 7, 10452-10464.	14.6	71
66	Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells. Experimental Cell Research, 2013, 319, 566-574.	2.6	22
67	Microfabricated polymeric vessel mimetics for 3-D cancer cell culture. Biomaterials, 2013, 34, 8301-8313.	11.4	23
68	Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity. Cancer, 2013, 119, 3076-3083.	4.1	39
69	Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20801-20806.	7.1	40
70	Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors. Cancer Research, 2012, 72, 2350-2361.	0.9	48
71	Cisplatin Sensitivity Mediated by WEE1 and CHK1 Is Mediated by miR-155 and the miR-15 Family. Cancer Research, 2012, 72, 5945-5955.	0.9	89
72	Rules to Prevent Conflict of Interest for Clinical Investigators Conducting Human Subjects Research. , 2012, , 139-146.		0

#	ARTICLE	IF	CITATIONS
73	Multidrug Resistanceâ€“Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 3197-3206.	7.0	60
74	The dynamics of drug resistance: A mathematical perspective. <i>Drug Resistance Updates</i> , 2012, 15, 90-97.	14.4	94
75	Drug resistance: Still a daunting challenge to the successful treatment of AML. <i>Drug Resistance Updates</i> , 2012, 15, 62-69.	14.4	218
76	Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1. <i>Drug Resistance Updates</i> , 2012, 15, 2-4.	14.4	35
77	Collateral sensitivity as a strategy against cancer multidrug resistance. <i>Drug Resistance Updates</i> , 2012, 15, 98-105.	14.4	269
78	Regulation and Expression of the ATP-Binding Cassette Transporter ABCG2 in Human Embryonic Stem Cells. <i>Stem Cells</i> , 2012, 30, 2175-2187.	3.2	35
79	Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-Glycoprotein. <i>PLoS ONE</i> , 2012, 7, e40717.	2.5	79
80	Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes. <i>Pharmacological Reviews</i> , 2012, 64, 706-721.	16.0	737
81	RAB8 Enhances TMEM205-Mediated Cisplatin Resistance. <i>Pharmaceutical Research</i> , 2012, 29, 643-650.	3.5	27
82	Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18708-18713.	7.1	381
83	Collateral Sensitivity of Multidrug-Resistant Cells to the Orphan Drug Tiopronin. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 4987-4997.	6.4	35
84	Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian Serous Carcinoma Effusions. <i>Molecular Pharmaceutics</i> , 2011, 8, 2080-2088.	4.6	31
85	The â€œSpecificâ€•P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2). <i>ACS Chemical Neuroscience</i> , 2011, 2, 82-89.	3.5	153
86	Inhibition of Multidrug Resistance by SV40 Pseudovirion Delivery of an Antigene Peptide Nucleic Acid (PNA) in Cultured Cells. <i>PLoS ONE</i> , 2011, 6, e17981.	2.5	18
87	Advances in the Molecular Detection of ABC Transporters Involved in Multidrug Resistance in Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 686-692.	1.6	62
88	Synthesis and Structureâ€“Activity Evaluation of Isatin-Î²-thiosemicarbazones with Improved Selective Activity toward Multidrug-Resistant Cells Expressing P-Glycoprotein. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5878-5889.	6.4	101
89	Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2593-2598.	7.1	50
90	Commentary: A Delicate Balance: Weighing the Effects of Conflict-of-Interest Rules on Intramural Research at the National Institutes of Health. <i>Academic Medicine</i> , 2010, 85, 1660-1662.	1.6	4

#	ARTICLE	IF	CITATIONS
91	Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. <i>Journal of Cellular Physiology</i> , 2010, 225, 822-828.	4.1	33
92	<i>N</i> -desmethyl-Loperamide Is Selective for P-Glycoprotein among Three ATP-Binding Cassette Transporters at the Blood-Brain Barrier. <i>Drug Metabolism and Disposition</i> , 2010, 38, 917-922.	3.3	40
93	Mechanisms of Multidrug Resistance in Cancer. <i>Methods in Molecular Biology</i> , 2010, 596, 47-76.	0.9	555
94	Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1637-1652.	6.3	241
95	Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 7449-7454.	7.1	233
96	Individualized Multidrug Resistance In Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 2491-2491.	1.4	0
97	A Dual-Fluorescence High-Throughput Cell Line System for Probing Multidrug Resistance. <i>Assay and Drug Development Technologies</i> , 2009, 7, 233-249.	1.2	53
98	Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2057-2066.	4.1	41
99	Influence of Melanosome Dynamics on Melanoma Drug Sensitivity. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1259-1271.	6.3	79
100	Structure of a multidrug transporter. <i>Nature Biotechnology</i> , 2009, 27, 546-547.	17.5	69
101	A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2009, 1794, 860-871.	2.3	281
102	Is resistance useless? Multidrug resistance and collateral sensitivity. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 546-556.	8.7	223
103	Synthesis, Activity, and Pharmacophore Development for Isatin- $\beta$ -thiosemicarbazones with Selective Activity toward Multidrug-Resistant Cells. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3191-3204.	6.4	146
104	Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 740-749.	3.3	142
105	Identification of gene signatures involved in the mechanisms of multidrug resistance. <i>Personalized Medicine</i> , 2009, 6, 133-134.	1.5	0
106	The Development of Gene Therapy: From Monogenic Recessive Disorders to Complex Diseases Such as Cancer. <i>Methods in Molecular Biology</i> , 2009, 542, 5-54.	0.9	31
107	Resistance to Cisplatin Results from Multiple Mechanisms in Cancer Cells. , 2009, , 83-88.		4
108	Disruption of microfilaments by cytochalasin B decreases accumulation of cisplatin in human epidermal carcinoma and liver carcinoma cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 977-984.	2.3	8



#	ARTICLE	IF	CITATIONS
109	Synonymous Mutations and Ribosome Stalling Can Lead to Altered Folding Pathways and Distinct Minima. <i>Journal of Molecular Biology</i> , 2008, 383, 281-291.	4.2	230
110	The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy. <i>Annual Review of Pharmacology and Toxicology</i> , 2008, 48, 495-535.	9.4	415
111	Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3081-3091.	4.1	151
112	SIRT1 Contributes in Part to Cisplatin Resistance in Cancer Cells by Altering Mitochondrial Metabolism. <i>Molecular Cancer Research</i> , 2008, 6, 1499-1506.	3.4	101
113	Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. <i>Pharmacogenomics</i> , 2007, 8, 29-39.	1.3	91
114	Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance-linked ABCG2 transporter. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 3287-3296.	4.1	89
115	Silent Polymorphisms Speak: How They Affect Pharmacogenomics and the Treatment of Cancer. <i>Cancer Research</i> , 2007, 67, 9609-9612.	0.9	219
116	A "Silent" Polymorphism in the <i>MDR1</i> Gene Changes Substrate Specificity. <i>Science</i> , 2007, 315, 525-528.	12.6	2,230
117	P-Glycoprotein is not present in mitochondrial membranes. <i>Experimental Cell Research</i> , 2007, 313, 3100-3105.	2.6	29
118	Comparison of Drug Transporter Levels in Normal Colon, Colon Cancer, and Caco-2 Cells: Impact on Drug Disposition and Discovery. <i>Molecular Pharmaceutics</i> , 2006, 3, 87-93.	4.6	45
119	The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research. <i>FEBS Letters</i> , 2006, 580, 998-1009.	2.8	472
120	Targeting multidrug resistance in cancer. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 219-234.	46.4	3,098
121	Endocytic Recycling Compartments Altered in Cisplatin-Resistant Cancer Cells. <i>Cancer Research</i> , 2006, 66, 2346-2353.	0.9	53
122	Selective Toxicity of NSC73306 in MDR1-Positive Cells as a New Strategy to Circumvent Multidrug Resistance in Cancer. <i>Cancer Research</i> , 2006, 66, 4808-4815.	0.9	162
123	Identification by Functional Cloning from a Retroviral cDNA Library of cDNAs for Ribosomal Protein L36 and the 10-kDa Heat Shock Protein that Confer Cisplatin Resistance. <i>Molecular Pharmacology</i> , 2006, 69, 1383-1388.	2.3	29
124	Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 9903-9907.	7.1	168
125	How Melanoma Cells Evade Chemotherapy. , 2006, , 591-603.		1
126	Defeating drug resistance in cancer. <i>Discovery Medicine</i> , 2006, 6, 18-23.	0.5	40



#	ARTICLE	IF	CITATIONS
127	Principal expression of two mRNA isoforms (ABCB $\hat{\epsilon}$ 5 $\hat{1}$ and ABCB $\hat{\epsilon}$ 5 $\hat{2}$ ) of the ATP-binding cassette transporter gene ABCB $\hat{\epsilon}$ 5 in melanoma cells and melanocytes. Pigment Cell & Melanoma Research, 2005, 18, 102-112.	3.6	82
128	Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum. Journal of Cellular Physiology, 2005, 202, 635-641.	4.1	52
129	A novel way to spread drug resistance in tumor cells: functional intercellular transfer of P-glycoprotein (ABCB1). Trends in Pharmacological Sciences, 2005, 26, 385-387.	8.7	86
130	Identification of Cytoskeletal [ <sup>14</sup> C]Carboplatin-Binding Proteins Reveals Reduced Expression and Disorganization of Actin and Filamin in Cisplatin-Resistant Cell Lines. Molecular Pharmacology, 2004, 66, 789-793.	2.3	29
131	Down-Regulation and Altered Localization of $\beta$ -Catenin in Cisplatin-Resistant Adenocarcinoma Cells. Molecular Pharmacology, 2004, 65, 1217-1224.	2.3	14
132	The Molecular Mysteries Underlying P-glycoprotein-Mediated Multidrug Resistance. Cancer Biology and Therapy, 2004, 3, 382-384.	3.4	15
133	Analysis of ATP-Binding Cassette Transporter Expression in Drug-Selected Cell Lines by a Microarray Dedicated to Multidrug Resistance. Molecular Pharmacology, 2004, 66, 1397-1405.	2.3	79
134	A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. Journal of Inorganic Biochemistry, 2004, 98, 1599-1606.	3.5	26
135	Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells. Experimental Cell Research, 2004, 293, 283-291.	2.6	25
136	Predicting drug sensitivity and resistance. Cancer Cell, 2004, 6, 129-137.	16.8	496
137	Modulation of Multidrug Resistance-Associated Protein 2 (Mrp2) and Mrp3 Expression and Function with Small Interfering RNA in Sandwich-Cultured Rat Hepatocytes. Molecular Pharmacology, 2004, 66, 1004-1010.	2.3	62
138	Codominance of cisplatin resistance in somatic cell hybrids. Journal of Cellular Physiology, 2003, 196, 63-69.	4.1	3
139	Cancer gene therapy: an awkward adolescence. Cancer Gene Therapy, 2003, 10, 501-508.	4.6	62
140	P-glycoprotein: from genomics to mechanism. Oncogene, 2003, 22, 7468-7485.	5.9	956
141	High Cloning Capacity of In Vitro Packaged SV40 Vectors with No SV40 Virus Sequences. Human Gene Therapy, 2003, 14, 167-177.	2.7	43
142	Gene Expression and Detection. , 2003, , 413-480.		0
143	P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Research, 2003, 63, 3084-91.	0.9	55
144	Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Research, 2003, 63, 5909-16.	0.9	78

#	ARTICLE	IF	CITATIONS
145	Drug selection with paclitaxel restores expression of linked IL-2 receptor $\alpha$ -chain and multidrug resistance (MDR1) transgenes in canine bone marrow. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3123-3128.	7.1	39
146	Mechanisms of Cancer Drug Resistance. Annual Review of Medicine, 2002, 53, 615-627.	12.2	2,284
147	Functional Characterization of Coding Polymorphisms in the HumanMDR1 Gene Using a Vaccinia Virus Expression System. Molecular Pharmacology, 2002, 62, 1-6.	2.3	154
148	Multidrug Resistance I: P-Glycoprotein. , 2002, , 247-254.		0
149	In Vitro-Packaged SV40 Pseudovirions as Highly Efficient Vectors for Gene Transfer. Human Gene Therapy, 2002, 13, 299-310.	2.7	38
150	Multidrug resistance in cancer: role of ATPâ€“dependent transporters. Nature Reviews Cancer, 2002, 2, 48-58.	28.4	4,873
151	Overview: ABC transporters and human disease. Journal of Bioenergetics and Biomembranes, 2001, 33, 453-458.	2.3	304
152	Decreased accumulation of [14c]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. Journal of Cellular Physiology, 2000, 183, 108-116.	4.1	91
153	Effect of ABC transporters on HIVâ€“1 infection: inhibition of virus production by the<i>MDR1</i> transporter. FASEB Journal, 2000, 14, 516-522.	0.5	87
154	Decreased accumulation of [14c]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptakeThis article is a US Government work and, as such, is in the public domain in the United States of America.. Journal of Cellular Physiology, 2000, 183, 108.	4.1	2
155	Engraftment of MDR1 and NeoR Gene-Transduced Hematopoietic Cells After Breast Cancer Chemotherapy. Blood, 1999, 94, 52-61.	1.4	142
156	BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER. Annual Review of Pharmacology and Toxicology, 1999, 39, 361-398.	9.4	1,940
157	A Single Amino Acid Residue Contributes to Distinct Mechanisms of Inhibition of the Human Multidrug Transporter by Stereoisomers of the Dopamine Receptor Antagonist Flupentixol. Biochemistry, 1999, 38, 6630-6639.	2.5	60
158	Both ATP Sites of Human P-Glycoprotein Are Essential but Not Symmetric. Biochemistry, 1999, 38, 13887-13899.	2.5	137
159	The Extracellular Loop between TM5 and TM6 of P-Glycoprotein Is Required for Reactivity with Monoclonal Antibody UIC2. Archives of Biochemistry and Biophysics, 1999, 367, 74-80.	3.0	31
160	Studies of Human MDR1-MDR2 Chimeras Demonstrate the Functional Exchangeability of a Major Transmembrane Segment of the Multidrug Transporter and Phosphatidylcholine Flippase. Molecular and Cellular Biology, 1999, 19, 1450-1459.	2.3	35
161	Human P-Glycoprotein Exhibits Reduced Affinity for Substrates during a Catalytic Transition State. Biochemistry, 1998, 37, 5010-5019.	2.5	245
162	Contribution to Substrate Specificity and Transport of Nonconserved Residues in Transmembrane Domain 12 of Human P-Glycoproteinâ€“. Biochemistry, 1998, 37, 16400-16409.	2.5	80

#	ARTICLE	IF	CITATIONS
163	HIV-1 Protease Inhibitors Are Substrates for the MDR1 Multidrug Transporter. <i>Biochemistry</i> , 1998, 37, 3594-3601.	2.5	482
164	Structural Flexibility of the Linker Region of Human P-Glycoprotein Permits ATP Hydrolysis and Drug Transport. <i>Biochemistry</i> , 1998, 37, 13660-13673.	2.5	99
165	[34] pHMDR-DHFR bicistronic expression system for mutational analysis of P-glycoprotein. <i>Methods in Enzymology</i> , 1998, 292, 474-480.	1.0	3
166	[42] Retroviral transfer of human MDR1 gene into human T lymphocytes. <i>Methods in Enzymology</i> , 1998, 292, 557-572.	1.0	12
167	Efficient Long-Term Coexpression of a Hammerhead Ribozyme Targeted to the U5 Region of HIV-1 LTR by Linkage to the Multidrug-Resistance Gene. <i>Oligonucleotides</i> , 1997, 7, 511-522.	4.3	15
168	DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus. <i>Nature Genetics</i> , 1997, 17, 483-486.	21.4	132
169	Altered Drug-stimulated ATPase Activity in Mutants of the Human Multidrug Resistance Protein. <i>Journal of Biological Chemistry</i> , 1996, 271, 1877-1883.	3.4	143
170	Characterization of Phosphorylation-defective Mutants of Human P-glycoprotein Expressed in Mammalian Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 1708-1716.	3.4	160
171	Interaction of bioactive hydrophobic peptides with the human multidrug transporter. <i>FASEB Journal</i> , 1994, 8, 766-770.	0.5	87
172	Putative "MDR enhancer" is located on human chromosome 20 and not linked to theMDR1 gene on chromosome 7. <i>Genes Chromosomes and Cancer</i> , 1994, 10, 267-274.	2.8	7
173	Efficient Expression of Drug-selectable Genes in Retroviral Vectors Under Control of an Internal Ribosome Entry Site. <i>Nature Biotechnology</i> , 1994, 12, 694-698.	17.5	58
174	Gene Transfer of Drug Resistance Genes Implications for Cancer Therapy. <i>Annals of the New York Academy of Sciences</i> , 1994, 716, 126-143.	3.8	35
175	The effect of ion channel blockers, immunosuppressive agents, and other drugs on the activity of the multi-drug transporter. <i>International Journal of Cancer</i> , 1993, 54, 456-461.	5.1	80
176	Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II. <i>Journal of Cellular Physiology</i> , 1993, 155, 414-425.	4.1	18
177	BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER. <i>Annual Review of Biochemistry</i> , 1993, 62, 385-427.	11.1	3,448
178	Pseudomonas Exotoxin Conjugated to Monoclonal Antibody MRK16 Specifically Kills Multidrug Resistant Cells in Cultured Renal Carcinomas and In Mdr-Transgenic Mice. <i>Journal of Urology</i> , 1993, 149, 174-178.	0.4	34
179	Is the multidrug transporter a flippase?. <i>Trends in Biochemical Sciences</i> , 1992, 17, 18-21.	7.5	700
180	ATP and GTP as alternative energy sources for vinblastine transport by P-170 in KB-V1 plasma membrane vesicles. <i>FEBS Letters</i> , 1992, 304, 256-260.	2.8	33

#	ARTICLE	IF	CITATIONS
181	Reduced mRNA levels for the multidrug-resistance genes in cAMP-dependent protein kinase mutant cell lines. <i>Journal of Cellular Physiology</i> , 1992, 152, 87-94.	4.1	30
182	Molecular manipulations of the multidrug transporter: a new role for transgenic mice <sup>1</sup>. <i>FASEB Journal</i> , 1991, 5, 2523-2528.	0.5	53
183	New Potent Verapamil Derivatives that Reverse Multidrug Resistance in Human Renal Carcinoma Cells and in Transgenic Mice Expressing the Human MDR 1 Gene. <i>Journal of Urology</i> , 1991, 146, 447-453.	0.4	41
184	Characterization by somatic cell genetics of a monoclonal antibody to theMDR1 gene product (P-glycoprotein): Determination of p-glycoprotein expression in multi-drug-resistant kb and cem cell variants. <i>International Journal of Cancer</i> , 1991, 47, 533-543.	5.1	37
185	Multidrug resistant transgenic mice as a novel pharmacologic tool. <i>BioEssays</i> , 1991, 13, 381-387.	2.5	29
186	Reversal of Drug Resistance in a Human Colon Cancer Xenograft Expressing MDR1 Complementary DNA by In Vivo Administration of MRK-16 Monoclonal Antibody. <i>Journal of the National Cancer Institute</i> , 1991, 83, 1386-1391.	6.3	75
187	In situLocalization of the Human Multidrug-resistance Gene mRNA Using Thymine-Thymine Dimerized Single-stranded cDNA. <i>Japanese Journal of Cancer Research</i> , 1990, 81, 949-955.	1.7	11
188	Expression of the multidrug resistance gene in myeloid leukemias. <i>Leukemia Research</i> , 1990, 14, 11-21.	0.8	118
189	Genetic basis of multidrug resistance of tumor cells. <i>Journal of Bioenergetics and Biomembranes</i> , 1990, 22, 593-618.	2.3	129
190	Retroviral transfer of a chimeric multidrug resistance&adenosine deaminase gene. <i>FASEB Journal</i> , 1990, 4, 1501-1507.	0.5	39
191	Expression of the human multidrug transporter in insect cells by a recombinant baculovirus. <i>Biochemistry</i> , 1990, 29, 2295-2303.	2.5	129
192	An epidermal growth factor-ricin a chain (EGF-RTA)-resistant mutant and an epidermal growth factor-Pseudomonas endotoxin (EGF-PE)-resistant mutant have distinct phenotypes. <i>Journal of Cellular Physiology</i> , 1989, 139, 51-57.	4.1	12
193	Detection of Multidrug Resistance (MDR1) Gene RNA Expression in Human Tumors by a Sensitive Ribonuclease Protection Assay. <i>Japanese Journal of Cancer Research</i> , 1989, 80, 1127-1132.	1.7	26
194	P-Glycoprotein gene (MDR1) cDNA from human adrenal: Normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. <i>Biochemical and Biophysical Research Communications</i> , 1989, 162, 224-231.	2.1	179
195	Expression of Multidrug Resistance Gene in Human Cancers. <i>Journal of the National Cancer Institute</i> , 1989, 81, 116-124.	6.3	1,214
196	Epidermal growth factor-dependent growth of human KB cells in a defined medium and altered growth factor requirements of KB mutants resistant to EGF-Pseudomonas exotoxin conjugates. <i>Journal of Cellular Physiology</i> , 1988, 135, 502-508.	4.1	8
197	Genetic characterization of human KB cell lines resistant to epidermal growth factor:Pseudomonas exotoxin conjugates. <i>Journal of Cellular Physiology</i> , 1988, 135, 527-532.	4.1	10
198	Measurement of Multidrug-Resistance Messenger RNA in Urogenital Cancers; Elevated Expression in Renal Cell Carcinoma is Associated with Intrinsic Drug Resistance. <i>Journal of Urology</i> , 1988, 139, 862-865.	0.4	140

#	ARTICLE	IF	CITATIONS
199	Multiple-Drug Resistance in Human Cancer. New England Journal of Medicine, 1987, 316, 1388-1393.	27.0	675
200	[9] Drug-resistant mutants: Selection and dominance analysis. Methods in Enzymology, 1987, 151, 113-121.	1.0	11
201	ATP-binding properties of P glycoprotein from multidrug-resistant KB cells. FASEB Journal, 1987, 1, 51-54.	0.5	209
202	Mutant KB cells with decreased EGF receptor expression: Biochemical characterization. Journal of Cellular Physiology, 1987, 133, 127-134.	4.1	10
203	The mdrl gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochemical and Biophysical Research Communications, 1986, 141, 956-962.	2.1	389
204	Internal duplication and homology with bacterial transport proteins in the mdrl (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 1986, 47, 381-389.	28.9	1,902
205	DNA-mediated transfer of cAMP resistance in CHO cells. Journal of Cellular Physiology, 1986, 127, 89-94.	4.1	4
206	Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somatic Cell and Molecular Genetics, 1985, 11, 117-126.	0.7	446
207	Verapamil enhances the toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin and antitransferrin receptor with pseudomonas exotoxin. Journal of Cellular Physiology, 1984, 120, 271-279.	4.1	52
208	Transfer of genes to chinese hamster ovary cells by DNA-mediated transformation. Somatic Cell Genetics, 1982, 8, 23-39.	2.7	37
209	Rous sarcoma virus transformed cells are resistant to cyclic AMP. Journal of Cellular Physiology, 1982, 111, 42-48.	4.1	10
210	Genetic evidence that a phorbol ester tumor promoter stimulates ornithine decarboxylase activity by a pathway that is independent of cyclic AMP-dependent protein kinases in CHO cells. Journal of Cellular Physiology, 1982, 113, 433-439.	4.1	48
211	Sodium butyrate affects expression of fibronectin on CHO cells: Specific increase in antibody-complement-mediated cytotoxicity. Journal of Cellular Physiology, 1980, 104, 163-170.	4.1	18
212	CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered $\beta^2$ -tubulin. Cell, 1980, 20, 29-36.	28.9	207
213	Prospects for Gene Therapy of HIV Infections and AIDS. , 0, , 291-318.		0
214	Clinical Applications of Gene Therapy in Cancer: Modification of Sensitivity to Therapeutic Agents. , 0, , 429-453.		0